Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Corline Biomedical AB (CLBIO) Stock Price & Analysis

CLBIO Stock Chart & Stats

SEK 13.85-SEK 0.35(-2.46%)
At close: 5:24 PM GMT+1
kr 14kr 16kr 183 Aug17 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
SEK 13.75 - SEK 14.40
52-Week Range
SEK 13.05 - SEK 20.20
Previous Close
SEK 14.30
Volume
N/A
Average Volume (3M)
7,931
Market Cap
SEK 371.09M
Enterprise Value
SEK 436.10M
Total Cash (Recent Filing)
SEK 32.99M
Total Debt (Recent Filing)
SEK 0
Price to Earnings (P/E)
―
Beta
0.43
Next Earnings
Nov 19, 2026 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance Sheet

The absence of debt removes leverage and refinancing pressure, while the sizable equity base provides a meaningful buffer against operating volatility. This financial flexibility can help Corline fund development, absorb losses, and pursue commercial opportunities without immediate dependence on creditors.

Revenue Growth

Strong trailing revenue growth indicates that Corline is gaining commercial traction for its blood-compatible technologies and products. If sustained, expanding sales can improve operating leverage, support broader customer adoption, and provide a foundation for eventual progress toward profitability.

Proprietary Blood-compatible Technology

Proprietary surface and biomaterial technologies address a fundamental biocompatibility problem across transplantation, medical devices, and advanced therapies. Applications across multiple blood-contacting workflows could support differentiated positioning and create opportunities for product sales, licensing, and partner integration.

Bears Say

Persistent Unprofitability

Continued substantial losses show that commercial traction has not yet translated into a sustainable earnings model. Persistently negative margins can constrain reinvestment, weaken returns on shareholder capital, and increase the importance of future revenue growth and cost discipline for achieving financial self-sufficiency.

Ongoing Cash Burn

Negative operating and free cash flow indicate that Corline is consuming cash to sustain its current operations and development activities. Unless operating performance improves, continued burn may require external funding over time, potentially limiting strategic flexibility despite the company’s debt-free balance sheet.

Unstable Earnings Performance

The shift from profitability to near break-even and then materially larger losses demonstrates limited earnings stability. Such volatility makes it harder to assess the durability of the business model, plan capital allocation, and establish confidence that revenue growth will consistently translate into improved financial results.

CLBIO FAQ

What was Corline Biomedical AB’s price range in the past 12 months?
Corline Biomedical AB lowest stock price was kr 13.05 and its highest was kr 20.20 in the past 12 months.
What is Corline Biomedical AB’s market cap?
Corline Biomedical AB’s market cap is kr 371.09M.
When is Corline Biomedical AB’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Corline Biomedical AB’s earnings last quarter?
Corline Biomedical AB released its earnings results on Aug 21, 2026. The company reported -kr 0.055 earnings per share for the quarter.
Is Corline Biomedical AB overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Corline Biomedical AB pay dividends?
Corline Biomedical AB does not currently pay dividends.
What is Corline Biomedical AB’s EPS estimate?
Corline Biomedical AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Corline Biomedical AB have?
Corline Biomedical AB has 26,133,118 shares outstanding.
What happened to Corline Biomedical AB’s price movement after its last earnings report?
Corline Biomedical AB reported an EPS of -kr 0.055 in its last earnings report. Following the earnings report the stock price went up 0.833%.
Which hedge fund is a major shareholder of Corline Biomedical AB?
Currently, no hedge funds are holding shares in SE:CLBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology